Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Baxter
Johnson and Johnson
McKesson
Express Scripts
Colorcon
AstraZeneca

Last Updated: December 3, 2022

CLINICAL TRIALS PROFILE FOR TREANDA


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


505(b)(2) Clinical Trials for Treanda

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials
Trial Type Trial ID Title Status Sponsor Phase Start Date Summary
New Combination NCT00974233 ↗ Study of Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed/Refractory CLL and SLL Completed Celgene Corporation Phase 2 2009-10-01 The purpose of this research is to evaluate a new combination of chemotherapy drugs for CLL/SLL using the drugs bendamustine (an intravenous chemotherapy drug), rituximab (an intravenous medication called a monoclonal antibody), and lenalidomide (an anti-cancer pill). The purpose of this study is to see if giving the chemotherapy pill lenalidomide after treatment with bendamustine and rituximab is able to prolong the period of time before the cancer starts growing again and causing symptoms.
New Combination NCT00974233 ↗ Study of Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed/Refractory CLL and SLL Completed University of Wisconsin, Madison Phase 2 2009-10-01 The purpose of this research is to evaluate a new combination of chemotherapy drugs for CLL/SLL using the drugs bendamustine (an intravenous chemotherapy drug), rituximab (an intravenous medication called a monoclonal antibody), and lenalidomide (an anti-cancer pill). The purpose of this study is to see if giving the chemotherapy pill lenalidomide after treatment with bendamustine and rituximab is able to prolong the period of time before the cancer starts growing again and causing symptoms.
>Trial Type >Trial ID >Title >Status >Phase >Start Date >Summary

All Clinical Trials for Treanda

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00139841 ↗ Safety and Efficacy of Treanda™ (Bendamustine HCl) in Patients With Indolent Non-Hodgkin's Lymphoma (NHL) Who Are Refractory to Rituximab Completed Cephalon Phase 3 2005-10-01 SUMMARY: This is a multi-center open label study to evaluate the safety and effectiveness of Treanda™ (also known as bendamustine HCl or SDX-105) in patients who have indolent Non-Hodgkin's lymphoma and have relapsed within a defined timeframe after taking rituximab (Rituxan®). Treanda will be given via 60-minute intravenous infusion on days 1 and 2 of every 21-day treatment cycle. Patients will be treated for 6 cycles unless they develop progressive disease or unacceptable toxicity. Those who continue to receive clinical benefit at end of 6 cycles may receive an additional 2 cycles. Following the end of treatment, patients will be followed for up to 2 years until disease progression or start of another anti-cancer therapy.
NCT00547534 ↗ Pilot Study of Bortezomib, Bendamustine and Rituximab on Non-Hodgkin's Lymphoma Completed Cephalon Phase 2 2007-10-01 The purpose of this study is to evaluate how non-Hodgkin's lymphoma that has not responded to, or that has returned after standard treatment, responds to bortezomib, rituximab and bendamustine, and also to see what effects this drug combination have on this cancer.
NCT00547534 ↗ Pilot Study of Bortezomib, Bendamustine and Rituximab on Non-Hodgkin's Lymphoma Completed Millennium Pharmaceuticals, Inc. Phase 2 2007-10-01 The purpose of this study is to evaluate how non-Hodgkin's lymphoma that has not responded to, or that has returned after standard treatment, responds to bortezomib, rituximab and bendamustine, and also to see what effects this drug combination have on this cancer.
NCT00547534 ↗ Pilot Study of Bortezomib, Bendamustine and Rituximab on Non-Hodgkin's Lymphoma Completed University of Rochester Phase 2 2007-10-01 The purpose of this study is to evaluate how non-Hodgkin's lymphoma that has not responded to, or that has returned after standard treatment, responds to bortezomib, rituximab and bendamustine, and also to see what effects this drug combination have on this cancer.
NCT00758693 ↗ Frontline Treatment With Bendamustine in Combination With Rituximab in Adults Age 65 or Older With Chronic Lymphocytic Leukemia (CLL) Withdrawn Cephalon Phase 2 2008-10-01 Many chemotherapy combinations may be used to treat patients with chronic lymphocytic leukemia (CLL). Although there are many options, a single, best option is not agreed upon by most cancer specialists. Bendamustine, a medicine recently approved for use in the United States, has been used in combination with rituximab in previous studies to treat patients whose CLL has returned after previous standard treatments. The purpose of this study is to determine whether bendamustine with rituximab is effective for the initial treatment of CLL for patients aged 65 and older.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Treanda

Condition Name

Condition Name for Treanda
Intervention Trials
Chronic Lymphocytic Leukemia 21
Multiple Myeloma 12
Mantle Cell Lymphoma 10
Lymphoma 10
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Treanda
Intervention Trials
Lymphoma 65
Leukemia, Lymphocytic, Chronic, B-Cell 37
Leukemia, Lymphoid 32
Leukemia 30
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Treanda

Trials by Country

Trials by Country for Treanda
Location Trials
United States 547
Canada 41
Australia 23
Italy 18
Poland 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Treanda
Location Trials
Texas 29
New York 28
California 26
Washington 19
Ohio 19
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Treanda

Clinical Trial Phase

Clinical Trial Phase for Treanda
Clinical Trial Phase Trials
Phase 3 12
Phase 2/Phase 3 2
Phase 2 38
[disabled in preview] 53
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Treanda
Clinical Trial Phase Trials
Completed 47
Active, not recruiting 16
Terminated 14
[disabled in preview] 21
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Treanda

Sponsor Name

Sponsor Name for Treanda
Sponsor Trials
National Cancer Institute (NCI) 24
Cephalon 19
M.D. Anderson Cancer Center 12
[disabled in preview] 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Treanda
Sponsor Trials
Other 103
Industry 82
NIH 24
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Baxter
Harvard Business School
Boehringer Ingelheim
Dow
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.